The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.
Quest said it will not acquire True Health's facilities or staff and that it expects the buy to expand the reach of its cardio-metabolic diagnostic services.
While some large health systems have developed internal tools for lab test utilization, a number of outside vendors are rolling out solutions of their own.
A jury last week determined Quest did not steal trade secrets from Cedars-Sinai or breach its contract with the hospital in developing a serological IBS test.
A JAMA study found that low-value diagnostic tests are common in inpatient settings, and machine learning systems can be used to identify those tests and reduce their overutilization.
The service uses Hc1's machine learning technology to collect and analyze lab data, allowing systems to identify areas where usage is inappropriate or inefficient.
While microbiology has traditionally relied heavily on manual processes, most workflows can now be automated, and AI tools promise to streamline it further.
The company recently launched an automated microbiology system in its Marlborough, Massachusetts laboratory using instruments from automation firm COPAN.
The lab beat the consensus Wall Street estimate on the top and bottom line, and maintained its revenue and adjusted EPS guidance for full-year 2019.